HMI-S201
We estimated the prevalence and correlates of mild cognitive impairment (MCI) among middle-aged and older diverse Hispanics/Latinos.Middle-aged and older diverse Hispanics/Latinos enrolled (n = 6377; 50-86 years) in this multisite prospective cohort study were evaluated for MCI using the National Institute on Aging-Alzheimer’s Association diagnostic criteria.
HMI Protein Vector (Human) (pPB-N-His) |
|||
| PV084026 | ABM | 500 ng | Ask for price |
HMI Protein Vector (Human) (pPM-C-HA) |
|||
| PV084027 | ABM | 500 ng | Ask for price |
HMI Protein Vector (Human) (pPM-C-His) |
|||
| PV084028 | ABM | 500 ng | Ask for price |
HMI 3'UTR GFP Stable Cell Line |
|||
| TU060007 | ABM | 1.0 ml | EUR 2333 |
HMI 3'UTR Luciferase Stable Cell Line |
|||
| TU010007 | ABM | 1.0 ml | EUR 2333 |
HMI Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728375 | ABM | 1.0 ug DNA | Ask for price |
HMI Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV728379 | ABM | 1.0 ug DNA | Ask for price |
HMI Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV728380 | ABM | 1.0 ug DNA | Ask for price |
HMI sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
| K0974305 | ABM | 3 x 1.0 ug | EUR 376 |
HMI sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|||
| K0974306 | ABM | 1.0 ug DNA | EUR 167 |
HMI sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|||
| K0974307 | ABM | 1.0 ug DNA | EUR 167 |
HMI sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|||
| K0974308 | ABM | 1.0 ug DNA | EUR 167 |
HMI Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV728376 | ABM | 1.0 ug DNA | Ask for price |
HMI Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV728377 | ABM | 1.0 ug DNA | Ask for price |
HMI Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV728378 | ABM | 1.0 ug DNA | Ask for price |
The overall MCI prevalence was 9.8%, which varied between Hispanic/Latino groups. Older age, high cardiovascular disease (CVD) risk, and elevated depressive symptoms were significant correlates of MCI prevalence. Apolipoprotein E4 (APOE) and APOE2 were not significantly associated with MCI.MCI prevalence varied among Hispanic/Latino backgrounds, but not as widely as reported in the previous studies.
CVD risk and depressive symptoms were associated with increased MCI, whereas APOE4 was not, suggesting alternative etiologies for MCI among diverse Hispanics/Latinos. Our findings suggest that mitigating CVD risk factors may offer important pathways to understanding and reducing MCI and possibly dementia among diverse Hispanics/Latinos.